MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
0.9102
-0.0098
-1.07%
After Hours: 0.8804 -0.0298 -3.27% 19:21 06/22 EDT
OPEN
0.9200
PREV CLOSE
0.9200
HIGH
0.9267
LOW
0.8736
VOLUME
248.99K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.7006
MARKET CAP
41.01M
P/E (TTM)
-2.7465
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNXT last week (0615-0619)?
Weekly Report · 20h ago
RenovoRx releases investor presentation outlining RenovoCath commercialization, TAMP oncology platform and Phase III TIGeR-PaC trial in pancreatic cancer
PUBT · 06/15 22:16
Weekly Report: what happened at RNXT last week (0608-0612)?
Weekly Report · 06/15 10:38
RenovoRx highlights case study on intra-arterial gemcitabine delivery via TAMP in pancreatic cancer
PUBT · 06/11 12:34
Weekly Report: what happened at RNXT last week (0601-0605)?
Weekly Report · 06/08 10:33
RenovoRx CEO Shaun Bagai presents at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
PUBT · 06/04 12:30
Ascendiant Remains a Buy on RenovoRx (RNXT)
TipRanks · 06/03 12:31
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Benzinga · 06/01 12:43
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.